JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265866

Human GDE1 (MIR16) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

GDE1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human GDE1 (MIR16) knockout HeLa cell line (AB265866)
  • Sanger seq

Unknown

Sanger Sequencing - Human GDE1 (MIR16) knockout HeLa cell line (AB265866)

Homozygous : 1 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265866-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265866-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265866 Human GDE1 (MIR16) knockout HeLa cell line", "number":"AB265866-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265866-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265866-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265866 Human GDE1 (MIR16) knockout HeLa cell line", "number":"AB265866-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265866-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265866 Human GDE1 (MIR16) knockout HeLa cell line", "number":"AB265866-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265866-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265866 Human GDE1 (MIR16) knockout HeLa cell line", "number":"AB265866-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
GDE1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MIR16 also known as microRNA-16 is a small non-coding RNA molecule typically around 22 nucleotides in length. This microRNA engages in the post-transcriptional regulation of gene expression impacting various mRNAs by binding and either degrading them or inhibiting their translation. MIR16 is expressed in numerous human tissues including the lungs heart and spleen indicating its broad functional significance in the body.
Biological function summary

MIR16 regulates cell cycle progression and apoptosis playing a role in maintaining cellular homeostasis. It is part of the microRNA-induced silencing complex (RISC) enabling it to mediate gene silencing efficiently. By influencing the expression of genes involved in the cell cycle MIR16 helps control cell proliferation and programmed cell death which are important processes for normal cellular function and response to stress.

Pathways

MIR16 is involved in the cell cycle and apoptosis signaling pathways. It interacts with key proteins such as cyclin D1 and Bcl-2 which are essential for cell cycle regulation and apoptosis respectively. By modulating these pathways MIR16 contributes to maintaining the balance between cell survival and death which is necessary to prevent abnormal cell growth.

MIR16 has connections to cancer and cardiovascular diseases. Aberrant expression of MIR16 can lead to uncontrolled cell proliferation linking it to cancer progression particularly in chronic lymphocytic leukemia where it shows reduced expression. Moreover its role in regulating apoptosis implicates MIR16 in cardiovascular diseases where its dysregulation can impact heart function. The interaction with proteins such as Bcl-2 in these conditions highlights its potential as a therapeutic target in disease management.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com